Non-conventional analgesics - novel non-peptidic antagonists of bradykinin
FP4 — Training and Mobility of Researchers
- Duration
- 1997-02-16 → 2000-02-15
- EU contribution
- —
- Participants
- 2
- Scheme
- RGI
Lines connect the coordinator with its partners. CORDIS does not always give exact coordinates for projects before 2014. These points are placed at city or country level.
Project objective
Research objectives and content The aims of this project are the design and synthesis of new non-conventional analgesics. Bradykinin, a peptide of nine aminoacid residues, is the most potent of the endogenous algogenic substances. Thus, antagonist of bradykinin have a great interest in the treatment and prevention of pain. Since peptidic antagonists are expensive and non-active orally, there is a great interest in the development I of non-peptidic antagonists. The non-peptidic antagonists known until now will be theoretically studied to develop the basic pharmacophore. Then, new derivatives will be design to fullfil that pharmacophore and those derivatives l more interesting will be synthesized and characterized. Subsequently, the analgesic activity will be | evaluated by an experienced group from the Faculty of Medicine of the U. Complutense of Madrid (Spain). In a feed-back process the biological results will be incorporated into the design and synthesis steps to improve the analgesic response. Training contents (objective, benefit and expected impact) Training in molecular modeling and drug design will open new perspectives to the applicant (in a future job search). Moreover, training in synthesis and spectroscopy analysis (nmr, uv, etc.) is fundamental for an organic chemist. Links with industry/industrial relevance (22) Members of the research group have and have had contracts with different pharmaceutical companies.
Original text from CORDIS.
Participants
Links
Data: CORDIS, © European Union